Neurocritical Care

, Volume 17, Issue 3, pp 388–394 | Cite as

Treatment of Elevated Intracranial Pressure with Hyperosmolar Therapy in Patients with Renal Failure

  • Karen G. Hirsch
  • Todd Spock
  • Matthew A. Koenig
  • Romergryko G. Geocadin
Original Article



To evaluate the use of hyperosmolar therapy in the management of elevated intracranial pressure (ICP) and transtentorial herniation (TTH) in patients with renal failure and supratentorial lesions.


Patients with renal failure undergoing renal replacement therapy treated with 23.4% saline (30–60 mL) and/or mannitol for high ICP or clinical evidence of TTH were analyzed in a retrospective cohort.


The primary outcome measure was reversal of TTH or ICP crisis. Secondary outcome measures were modified Rankin scale on hospital discharge, survival to hospital discharge, and adverse effects. Of 254 subjects over 7 years, 6 patients with end-stage renal disease had 11 events. All patients received a 23.4% saline bolus, along with mannitol (91%), hypertonic saline (HS) maintenance fluids (82%), and surgical interventions (n = 2). Reversal occurred in 6/11 events (55%); 2 of 6 patients survived to discharge. ICP recording of 6 TTH events showed a reduction from ICP of 41 ± 3.8 mmHg (mean ± SEM) with TTH to 20.8 ± 3.9 mmHg (p = 0.05) 1 h after the 23.4% saline bolus. Serum sodium increased from 141.4 to 151.1 mmol/L 24 h after 23.4% saline bolus (p = 0.001). No patients were undergoing hemodialysis at the time of the event. There were no cases of pulmonary edema, clinical volume overload, or arrhythmia after HS.


Treatment with hyperosmolar therapy, primarily 23.4% saline solution, was associated with clinical reversal of TTH and reduction in ICP and had few adverse effects in this cohort. Hyperosmolar therapy may be safe and effective in patients with renal failure and these initial findings should be validated in a prospective study.


Hypertonic saline Intracranial pressure Transtentorial herniation ICP Renal failure 



Dr. Geocadin was supported by NIH Grant #R01HL071568.




  1. 1.
    Qureshi AI, Geocadin RG, Suarez JI, Ulatowski JA. Long-term outcome after medical reversal of transtentorial herniation in patients with supratentorial mass lesions. Crit Care Med. 2000;28:1556–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Skoglund TS, Nellgard B. Long-term outcome after transient transtentorial herniation in patients with traumatic brain injury. Acta Anaesthesiol Scand. 2005;49:337–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Bhardwaj A. Osmotherapy in neurocritical care. Curr Neurol Neurosci Rep. 2007;7(6):513–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Harukuni I, Kirsch JR, Bhardwaj A. Osmotherapy in acute brain resuscitation. J Anesth. 2002;16:229–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema, intracranial hypertension. Crit Care Med. 2000;28:3301–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Paczynski RP. Osmotherapy. Basic concepts and controversies. Crit Care Clin. 1997;13:105–29.PubMedCrossRefGoogle Scholar
  7. 7.
    Schell RM, Applegate RL II, Cole DJ. Salt, starch, and water on the brain. J Neurosurg Anesthesiol. 1996;8:178–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Zornow MH. Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. J Neurosurg Anesthesiol. 1996;8:175–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen CH, Toung TJ, Sapirstein A, et al. Effect of duration of osmotherapy on blood–brain barrier disruption and regional cerebral edema after experimental stroke. J Cereb Blood Flow Metab. 2006;26:951–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Toung TJK, Hurn PD, Traystman RJ, et al. Global brain water increases after experimental focal cerebral ischemia: effect of hypertonic saline. Crit Care Med. 2002;30:644–9.PubMedCrossRefGoogle Scholar
  11. 11.
    The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol. J Neurotrauma 2000;17:521–525.Google Scholar
  12. 12.
    Koenig MA, Bryan M, Lewin JL, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hypertonic saline. Neurology. 2008;70:1023–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Qureshi A, Suarez JI, Bhardwaj A, et al. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. Crit Care Med. 1998;26:440–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Huang SJ, Chang L, Han YY, et al. Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury. Surg Neurol. 2006;65:539–46.PubMedCrossRefGoogle Scholar
  15. 15.
    White H, Cook D, Venkatesh B. The use of hypertonic saline for treating intracranial hypertension after traumatic brain injury. Anesth Analg. 2006;102:1836–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Berger S, Schurer L, Hartl R, Messmer K, Baethmann A. Reduction of post-traumatic intracranial hypertension by hypertonic/hyperoncotic saline/dextran and hypertonic mannitol. Neurosurgery. 1995;37:98–107.PubMedCrossRefGoogle Scholar
  17. 17.
    Khanna S, Davis D, Peterson B, et al. Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury. Crit Care Med. 2000;28:1144–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Bhardwaj A, Ulatowski JA. Hypertonic saline solutions in brain injury. Curr Opin Crit Care. 2004;10:126–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke. 2002;33:136–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Qureshi AI, Wilson DA, Traystman RJ. Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline. Neurosurgery. 1999;44:1055–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Qureshi AI, Wilson DA, Traystman RJ. Treatment of transtentorial herniation unresponsive to hyperventilation using hypertonic saline in dogs: effect on cerebral blood flow and metabolism. J Neurosurg Anesthesiol. 2002;14:22–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Suarez JI, Qureshi AI, Bhardwaj A, et al. Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med. 1998;26:1118–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Ware ML, Nemani VM, Meeker M, Lee C, Morabito DJ, Manley GT. Effects of 23.4% saline solution in reducing intracranial pressure in patients with traumatic brain injury: a preliminary study. Neurosurgery. 2005;57:727–36.PubMedCrossRefGoogle Scholar
  24. 24.
    Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should HD patients with AFib undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis. 2007;50:421–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Brouns De Deyn. Neurologic complications in renal failure: a review. Clinical Neurol Neurosurg. 2004;107(1):1–16.CrossRefGoogle Scholar
  26. 26.
    Gondo Fujitsu, et al. Comparison of five modes of dialysis in neurosurgical patients with renal failure. Neurol Med Chir (Tokyo). 1989;29(12):1125–31.CrossRefGoogle Scholar
  27. 27.
    Davenport A. Renal replacement therapy for the patient with acute traumatic brain injury and severe acute kidney injury. Contrib Nephrol. 2007;156:333–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Fletcher Bergman, Feucht Blostein. Continuous renal replacement therapy for refractory intracranial hypertension. Neurocrit Care. 2009;11(1):101–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Wijdicks EF, Zubkov AY. Re: Reversal of transtentorial herniation with hypertonic saline. Neurology. 2009;72(2):200.PubMedCrossRefGoogle Scholar
  30. 30.
    Diringer MN, Zazulia AR. Osmotic therapy fact and fiction. Neurocrit Care. 2004;1(2):219–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Paczynski RP, He YY, Diringer MN, Hsu CY. Multiple-dose mannitol reduces brain water content in a rat model of cortical infarction. Stroke. 1997;28(7):1437–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Lo WD, Betz AL, Schielke GP, Hoff JT. Transport of sodium from blood to brain in ischemic brain edema. Stroke. 1987;18:150–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Jaradat MI, Molitoris BA. Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol. 2002;22(6):459–73.PubMedGoogle Scholar
  34. 34.
    Froelich M, Ni Q, Wess C, Ougorets I, Härtl R. Continuous hypertonic saline therapy and the occurrence of complications in neurocritically ill patients. Crit Care Med. 2009;37(4):1433–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Kien ND, Kramer GC, White DA. Acute hypotension caused by rapid hypertonic saline infusion in anaesthetized dogs. Anesth Analg. 1991;73:597–602.PubMedGoogle Scholar
  36. 36.
    Zhang D, Sato T, Gong D, Fu L, Dai S, Xu H, Wu Q, Wang D, Peng Y, Sun Y. Neural reflex hypotension induced by very small dose of hypertonic NaCl solution in rats. Chin J Physiol. 2009;52(1):8–15.PubMedCrossRefGoogle Scholar
  37. 37.
    Stiver SI, Gean AD, Manley GT. Survival with good outcome after cerebral herniation and Duret hemorrhage caused by traumatic brain injury. J Neurosurg. 2009;110(6):1242–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Kamel H, Navi BB, Nakagawa K, Hemphill JC 3rd, Ko NU. Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med. 2011;39(3):554–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Karen G. Hirsch
    • 1
    • 7
  • Todd Spock
    • 1
    • 2
    • 3
  • Matthew A. Koenig
    • 4
    • 5
  • Romergryko G. Geocadin
    • 1
    • 2
    • 3
    • 6
  1. 1.Department of NeurologyThe Johns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of NeurosurgeryThe Johns Hopkins Medical InstitutionsBaltimoreUSA
  3. 3.Department of Anesthesia and Critical Care MedicineThe Johns Hopkins Medical InstitutionsBaltimoreUSA
  4. 4.Department of Neurocritical CareThe Queen’s Medical CenterHonoluluUSA
  5. 5.Department of Medicine, The John A. Burns School of MedicineUniversity of HawaiiHonoluluUSA
  6. 6.Division of Neuroscience Critical CareJohns Hopkins University School of MedicineBaltimoreUSA
  7. 7.Division of Neurocritical CareUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations